Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Alpha Cognition Inc
ACOG
Healthcare
Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062...
is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ACOG)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
(21)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Nov 08, 2021 5:28pm
$ACOG DD
For those interested in the biopharma sector Alpha Cognition Inc. ( $ACOG.V ACOGF ) is a company that is in the clinical stages of developing treatments for Alzheimer's Disease, ALS, and other
...more
(26)
•••
XeniaTechie
X
View Profile
View Bullboard History
Post by
XeniaTechie
on Nov 05, 2021 12:20pm
Alpha Cognition big potential to take massive ADmarket share
Alpha Cognition has immense potential to capture major market share of ALZ treatment, a $355B market expected to grow to $1.1T by 2050. A-1062 taps into the gap where 8/10 #AD patients cease treatment
...more
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company
posted Dec 22, 2024 9:00am by
Voyageur Pharmaceuticals Ltd
-
|
Voyageur is securing supply chains in North America for barium, iodine and fullerene drug development and is aiming to gain efficiencies in production of contrast media products. The company anticipates this LOI will expand Voyageur’s project portfolio and diversify the Company’s product mix. The global contrast media market is valued at $6.3 billion with GE HealthCare projecting it will double over the next decade. ...read more
(273)
•••
partystocker
X
View Profile
View Bullboard History
Post by
partystocker
on Nov 04, 2021 11:26am
$ACOG getting some major recognition from analysts
Alpha Cognition Inc. $ACOG/$ACOG.V shares are recovering nicely from a small dip earlier this month. $ACOG’s Alzheimer's drugs are getting some serious attention from analysts. In a
...more
(26)
•••
XeniaTechie
X
View Profile
View Bullboard History
Post by
XeniaTechie
on Nov 02, 2021 12:42pm
Alpha 1062 might be the next best-in-class ALZ drug
More coverage on $ACOG late-stage drug, Alpha-1062, this is promising as the next best-in-class Alzheimer's drug - they may be in position to file NDA in 2022 - once approved, insight on strong
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Post by
waves1
on Nov 01, 2021 4:17pm
Deep Dive into $ACOG
I found this really informative interview with the CEO of Alpha Cognition Inc. ($ACOG $ACOG.v $ACOGF) that I wanted to share. It gives a solid overview of $ACOG in general, as well as gives
...more
(21)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Oct 29, 2021 3:01pm
Interview with $ACOG CEO hilights IPO financing
If you're interested in the biopharma sector I would highly recommend checking out Alpha Cognition Inc. ( $ACOG.V ACOGF ). $ACOG is a biopharmaceutical company that is in clinical stages
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Post by
waves1
on Oct 28, 2021 1:42pm
$ACOG could offer best-in-class treatment option
"ALPHA-1062 could offer a potential best-in-class treatment option" If their drug gets approval, Alpha Cognition Inc. ($ACOG $ACOG.v $ACOGF) is going to be clearly set apart
...more
(26)
•••
XeniaTechie
X
View Profile
View Bullboard History
Post by
XeniaTechie
on Oct 27, 2021 12:25pm
Solid updates from ACOG CEO during the SH interview
Sharing a solid interview with $ACOG CEO Michael McFadden discussing updates. $ACOGF is still seriously undervalued - with a late stage program in a $5B market - they have strong conviction backed by
...more
(273)
•••
partystocker
X
View Profile
View Bullboard History
Post by
partystocker
on Oct 26, 2021 4:34pm
$ACOG CEO says they've been able to accelerate workflow
Alpha Cognition Inc. expecting prices to test $1.40. Prices are already up 8.7% this week. Just found this interview with the CEO of $ACOG. He talks about how their company is completely virtual
...more
(26)
•••
XeniaTechie
X
View Profile
View Bullboard History
Post by
XeniaTechie
on Oct 25, 2021 1:12pm
Globe names ACOG a speculative buy
Globe and Mail rates Alpha Cognition $ACOG a 'speculative buy' - The patent for A-1062 with reduced side-effects common across other AD drugs is a massive potential market, touting an
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Post by
waves1
on Oct 22, 2021 5:45pm
Informative $ACOG CEO interview
Found a great interview with the CEO of Alpha Cognition Inc. ( $ACOG $ACOG.v $ACOGF) from last month - super informative regarding the upcoming trial, as well as their additional pipeline projects
...more
(15)
•••
firstandgoal43
X
View Profile
View Bullboard History
Post by
firstandgoal43
on Oct 20, 2021 7:21pm
$ACOG - Reports Looking Good
$ACOG Up another 6% today alone but still trading at a discount to the PP. They also had a huge presentation on October 12th at the LD Micro Main Event. Btw $ACOG is looking wayyy more reputable than
...more
(144)
•••
culturedpiggy01
X
View Profile
View Bullboard History
Post by
culturedpiggy01
on Oct 19, 2021 6:38pm
Updates on $ACOG.Vs presentation at LD Micro Main Event!
good to see $ACOG.V in the green, still recapping their presentation at the LD Micro Main Event. It was good to see them touch base on their Alphas programs and give an in-dept comparative analysis
...more
(10)
•••
ferret_ca
X
View Profile
View Bullboard History
Comment by
ferret_ca
on Oct 19, 2021 4:22pm
RE:RE:$ACOG - not much movement td
well that blurb gave it a nice little boost today, not a lot shares out so it won't take much good news to get things really rolling here, it sounds like this alzheimer drug could go thru trials
...more
(10)
•••
ferret_ca
X
View Profile
View Bullboard History
Comment by
ferret_ca
on Oct 19, 2021 9:46am
RE:$ACOG - not much movement td
a good blurb in the globe investor this morning, an analyst from iAcapital gives it $5 price target and basicaly says it has an exceptionally high probability of success. I initiated a starting
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments